Crystal Structure of Steroid Reductase SRD5A Reveals Conserved Steroid Reduction Mechanism
Overview
Authors
Affiliations
Steroid hormones are essential in stress response, immune system regulation, and reproduction in mammals. Steroids with 3-oxo-Δ structure, such as testosterone or progesterone, are catalyzed by steroid 5α-reductases (SRD5As) to generate their corresponding 3-oxo-5α steroids, which are essential for multiple physiological and pathological processes. SRD5A2 is already a target of clinically relevant drugs. However, the detailed mechanism of SRD5A-mediated reduction remains elusive. Here we report the crystal structure of PbSRD5A from Proteobacteria bacterium, a homolog of both SRD5A1 and SRD5A2, in complex with the cofactor NADPH at 2.0 Å resolution. PbSRD5A exists as a monomer comprised of seven transmembrane segments (TMs). The TM1-4 enclose a hydrophobic substrate binding cavity, whereas TM5-7 coordinate cofactor NADPH through extensive hydrogen bonds network. Homology-based structural models of HsSRD5A1 and -2, together with biochemical characterization, define the substrate binding pocket of SRD5As, explain the properties of disease-related mutants and provide an important framework for further understanding of the mechanism of NADPH mediated steroids 3-oxo-Δ reduction. Based on these analyses, the design of therapeutic molecules targeting SRD5As with improved specificity and therapeutic efficacy would be possible.
Gjorgoska M, Sturm L, Rizner T Front Endocrinol (Lausanne). 2024; 15:1404804.
PMID: 39205690 PMC: 11349532. DOI: 10.3389/fendo.2024.1404804.
Ali K, Li W, Wu G Heliyon. 2024; 10(14):e34322.
PMID: 39108866 PMC: 11301207. DOI: 10.1016/j.heliyon.2024.e34322.
Sex hormones differently regulate lipid metabolism genes in primary human hepatocytes.
Seidemann L, Lippold C, Rohm C, Eckel J, Schicht G, Matz-Soja M BMC Endocr Disord. 2024; 24(1):135.
PMID: 39090659 PMC: 11292922. DOI: 10.1186/s12902-024-01663-9.
A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis.
Wilson M, Kentache T, Althoff C, Schulz C, de Bettignies G, Cabrera G Cell. 2024; 187(14):3585-3601.e22.
PMID: 38821050 PMC: 11250103. DOI: 10.1016/j.cell.2024.04.041.
Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis.
Pan Y, Zhang H, Li M, He T, Guo S, Zhu L Gut Microbes. 2024; 16(1):2356284.
PMID: 38769683 PMC: 11110704. DOI: 10.1080/19490976.2024.2356284.